December 27, 2019 - The court granted in part and denied in part the defendants' motion to dismiss.

May 3, 2019 - A motion to dismiss the amended complaint was filed.

February 28, 2019 - An amended complaint was filed.

February 8, 2018 - An investor in shares of Johnson & Johnson (NYSE: JNJ) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Johnson & Johnson in connection with certain allegedly false and misleading statements made between February 22, 2013, and February 7, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Johnson & Johnson (NYSE: JNJ) common shares between February 22, 2013, and February 7, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 22, 2013, and February 7, 2018, the defendants made false or misleading statements, and failed to disclose that J&J has known for decades that its talc products include asbestos fibers and that the exposure to those fibers can cause ovarian cancer and mesothelioma. Johnson & Johnson's denials that talc could cause cancer and mesothelioma were materially false and misleading, and the company concealed contingent liabilities and loss of future revenues from the product.

Johnson & Johnson reported that its Total Revenue rose from $71.89 billion in 2016 to $7645 billion in 2017 and that its Net Income declined from $16.54 billion in 2016 to $1.3 billion in 2017.

On February 5, 2018,an article was published stating that “court proceedings could expose potentially damaging documents” related to Johnson & Johnson’s talc products, such as Johnson’s Baby Powder.

On February 7, 2018, the Beasley Allen Law Firm announced that “[l]awsuits filed by ovarian cancer and mesothelioma victims are revealing never-before-seen documents from Johnson & Johnson and talc supplier, Imerys, that shed light on just how prevalent asbestos and heavy metals are in the talc used in Baby Powder.” The release stated that “[i]nternal Johnson & Johnson documents from 1972 note that asbestos was found in 100 percent of talc samples tested at the time, but this information was never released publicly.” It further stated that Johnson & Johnson stopped funding a project designed to test talc samples for asbestos contamination once a majority of the sample batches were found to be positive for asbestos.

Shares of Johnson & Johnson (NYSE: JNJ) declined to $125.44 per share on February 9, 2018.